Foundation supports broad RSV vaccination in immunocompromised adults

Broadly, the Immune Deficiency Foundation (IDF) follows vaccine recommendations issued by the American Academy of Pediatrics (AAP) for children under 18 years of age and the American Academy of Family Physicians (AAFP) for adults aged 18 and older.

However, in March 2026, the Infectious Diseases Society of America (IDSA) published recommendations on the prevention of respiratory syncytial virus (RSV) infection specifically in immunocompromised individuals. IDSA recommends that all individuals aged 18 years and older who are immunocompromised receive one dose of an RSV vaccine. This differs from AAFP guidance, which recommends vaccination for immunocompromised individuals aged 50 years and older, as well as for pregnant individuals.

IDSA’s recommendation is based on published, real-world evidence of vaccine efficacy in immunocompromised individuals, who were excluded from the original clinical trials for the vaccines. Because these recommendations are tailored to immunocompromised populations, including individuals with primary immunodeficiency (PI), the foundation recommends following IDSA guidance for RSV vaccination in adults rather than AAFP guidance. This guidance has been reviewed and endorsed by the foundation’s Medical Advisory Committee.

Note that IDSA also recommends shared clinical decision making for RSV vaccination in children under 18. Currently, standard RSV vaccines have been not approved by the Food and Drug Administration (FDA) for use in children, therefore, the foundation does not support this recommendation at this time.